PMID- 34851742
OWN - NLM
STAT- MEDLINE
DCOM- 20220811
LR  - 20221207
IS  - 1942-7905 (Electronic)
IS  - 1942-7891 (Print)
IS  - 1942-7891 (Linking)
VI  - 25
IP  - 4
DP  - 2022 Aug
TI  - Successful Implementation of an All-or-None Diabetes Measure in 10 US Health 
      Systems.
PG  - 433-440
LID - 10.1089/pop.2021.0266 [doi]
AB  - Type 2 diabetes mellitus (T2DM) affects 31.5 million adults in the United States 
      and is commonly treated in primary care settings. One promising approach to 
      comprehensive care is to focus on an all-or-none diabetes bundle measure, which 
      ensures each patient meets a set of guideline-recommended measures. This requires 
      a practice-level coordinated strategy. The purpose of this initiative was to help 
      health care organizations (HCOs) improve the care and outcomes of patients with 
      T2DM using an all-or-none bundle measure. This observational study was carried 
      out in the context of a national best practices learning Collaborative that 
      implemented targeted interventions in primary care settings and measured success 
      using an all-or-none bundle measure. Ten AMGA member-HCOs, across 8 states, 
      treating nearly 300,000 adult patients with T2DM in primary care participated. 
      The primary measure, the Together 2 Goal((R)) Core Bundle, included hemoglobin A1c 
      (A1c) control (<8%), blood pressure (BP) control (<140/90 mmHg), lipid management 
      (prescribed a statin), and medical attention for nephropathy. All 10 HCOs 
      improved the Core Bundle measure during the 12-month Collaborative. The rate for 
      the Core Bundle improved from 40.2% to 42.8%, an absolute increase of 2.6% 
      (P < 0.001). In addition, 9 HCOs improved BP control, 8 improved lipid 
      management, 6 improved attention to nephropathy, and 4 improved A1c control. 
      Implementing interventions in primary care settings was successful in achieving 
      comprehensive care for an estimated additional 7700 people living with T2DM who 
      met all 4 components of the bundle measure during the 12-month intervention 
      period.
FAU - Grant, Cori Cohen
AU  - Grant CC
AD  - AMGA, Alexandria, Virginia, USA.
FAU - Chambers, Earlean
AU  - Chambers E
AD  - AMGA, Alexandria, Virginia, USA.
FAU - Rattelman, Cori
AU  - Rattelman C
AD  - AMGA, Alexandria, Virginia, USA.
FAU - Hamersky, Carol Mahler
AU  - Hamersky CM
AD  - Novo Nordisk, Plainsboro, New Jersey, USA.
FAU - Leng, Wichitah
AU  - Leng W
AD  - Novo Nordisk, Plainsboro, New Jersey, USA.
FAU - Kennedy, John
AU  - Kennedy J
AD  - AMGA, Alexandria, Virginia, USA.
FAU - Ciemins, Elizabeth L
AU  - Ciemins EL
AUID- ORCID: 0000-0003-1262-7946
AD  - AMGA, Alexandria, Virginia, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20211129
PL  - United States
TA  - Popul Health Manag
JT  - Population health management
JID - 101481266
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Lipids)
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/therapy
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Lipids
MH  - United States
PMC - PMC9419939
OTO - NOTNLM
OT  - hemoglobin A1c
OT  - hypertension
OT  - nephropathy
OT  - quality measure
OT  - statin
COIS- Dr. Hamersky and Dr. Leng are employees of Novo Nordisk, Inc. For the remaining 
      authors, no competing interests were declared.
EDAT- 2021/12/02 06:00
MHDA- 2022/08/12 06:00
PMCR- 2022/08/08
CRDT- 2021/12/01 17:14
PHST- 2021/12/02 06:00 [pubmed]
PHST- 2022/08/12 06:00 [medline]
PHST- 2021/12/01 17:14 [entrez]
PHST- 2022/08/08 00:00 [pmc-release]
AID - 10.1089/pop.2021.0266 [pii]
AID - 10.1089/pop.2021.0266 [doi]
PST - ppublish
SO  - Popul Health Manag. 2022 Aug;25(4):433-440. doi: 10.1089/pop.2021.0266. Epub 2021 
      Nov 29.